Otonomy to Participate in Two Upcoming Investor Conferences
26 nov. 2019 16h05 HE
|
Otonomy, Inc.
SAN DIEGO, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy Reports Third Quarter 2019 Financial Results and Provides Corporate Update
05 nov. 2019 16h13 HE
|
Otonomy, Inc.
Results from three clinical trials expected in 2020 including the Phase 3 trial of OTIVIDEX™ in Ménière’s diseaseBroadest pipeline in neurotology field expanded to include gene therapy collaboration...
Otonomy to Report Third Quarter 2019 Financial Results and Provide Corporate Update
29 oct. 2019 16h05 HE
|
Otonomy, Inc.
SAN DIEGO, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy to Present at the Cantor Global Healthcare Conference
26 sept. 2019 16h05 HE
|
Otonomy, Inc.
SAN DIEGO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy Initiating Phase 1/2 Clinical Trial of OTO-413 in Hearing Loss
17 sept. 2019 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Auris Medical Receives FDA and EMA Guidance for Keyzilen® Late-Stage Clinical Development Program
13 sept. 2019 09h00 HE
|
Auris Medical AG
Hamilton, Bermuda, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
Auris Medical Announces Formation of Scientific Advisory Board for Tinnitus Programs
26 août 2019 09h00 HE
|
Auris Medical AG
Hamilton, Bermuda, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
Otonomy Reports Second Quarter 2019 Financial Results and Provides Corporate Update
01 août 2019 16h20 HE
|
Otonomy, Inc.
Clinical-stage programs on track with results expected from three trials in 2020Current capital funds operations into 2021 Conference call and webcast today at 4:30 p.m. EDT SAN DIEGO, Aug. 01,...
Otonomy to Report Second Quarter 2019 Financial Results and Provide Corporate Update
25 juil. 2019 16h05 HE
|
Otonomy, Inc.
SAN DIEGO, July 25, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
American Tinnitus Association Elects Five New Members to its Board of Directors
09 juil. 2019 09h17 HE
|
American Tinnitus Association
Vienna, Virginia, July 09, 2019 (GLOBE NEWSWIRE) -- The American Tinnitus Association (ATA) has elected five members to serve three-year terms on its board of directors, according to Dr. Jill...